Status:
COMPLETED
Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis
Lead Sponsor:
Makerere University
Collaborating Sponsors:
University of Liverpool
Conditions:
HIV Infections
Tuberculosis
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Triomune is the most commonly prescribed treatment for HIV infection in Uganda. Triomune is manufactured by a generic drug company and consists of three drugs combined in a single pill given twice dai...
Detailed Description
Many patients in Uganda are co-infected with HIV and TB and require simultaneous treatment for both diseases. There is a paucity of data on the complex pharmacokinetic interactions between antiretrovi...
Eligibility Criteria
Inclusion
- Ability to provide full informed written consent
- Confirmed diagnosis of HIV infection
- On rifampicin therapy for at least two weeks
- Clinical criteria for commencing antiretroviral therapy
Exclusion
- Hemoglobin \< 8g/dl
- Liver and renal function tests \> 3 times the upper limit of normal
- Pregnancy
- Use of know inhibitors or inducers of Cytochrome P450 or P-glycoprotein.
- Use of herbal medications
- Intercurrent Illness
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00617643
Start Date
May 1 2008
End Date
December 1 2010
Last Update
December 6 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Infectious Diseases Institute, Faculty of Medicine, Makerere University
Kampala, Uganda